概述
Evidence must match the context of use and the consequences of error. A promising retrospective model is not automatically credible for a clinical or regulatory decision.
重點摘要
- State context of use and endpoint.
- Use risk-based validation and multidisciplinary review.
- Manage the model across its lifecycle.
深入探討
Define the intended use, population, endpoint, and decision boundary. A model prioritizing compounds for laboratory study differs from one used to inform a clinical submission. Preserve the distinction between exploratory hypotheses and evidence used to support safety or effectiveness. Use documented data provenance, quality controls, and appropriate validation. Check batch effects, missing measurements, site differences, and whether the outcome label is a meaningful proxy. For time-dependent or prospective decisions, use evaluation data that respects when information becomes available. FDA and EMA guiding principles emphasize human-centered design, risk-based approaches, context of use, multidisciplinary expertise, data governance, performance assessment, and lifecycle management. Treat these as a framework for evidence and accountability, not as a blanket approval of a model. Retain versioned protocols, model outputs, and review decisions. Monitor performance after deployment and define how a change in data, assay, or model triggers reassessment.
04工作範例
Move from discovery to evidence carefully
Imagine a model ranking ten compounds for laboratory testing with a strong retrospective score.
Before using it for a patient-safety decision, define the prospective endpoint and evaluate on data collected under that protocol.
Record the uncertainty and require domain review at the new decision boundary.
它顯示了什麼
The constructed example separates exploratory prioritization from regulated evidence.
現實世界的實施
Hold out a study site when evaluating whether a biomarker model transfers.
Document context of use before using an AI result in a regulated submission.
付諸實踐
為什麼這很重要
- 背景與規則. 產業背景決定了人工智慧創意能否與現實接觸。
- 品質管控. 領域約束會影響可接受的錯誤率和監督模型。
- 配裝選擇. 成功的部署使技術能力與第一線工作流程保持一致。
留意
- 監理要求可能會使原本強大的原型失效。
- 歷史資料可能會編碼損害特定社區的偏見。
- 遺留系統可能會造成整合瓶頸和隱性成本。
後續步驟
- 讓領域專家參與從問題框架到評估的整個過程。
- 在啟動前設計審計追蹤和文件。
- 儘早驗證合規性和安全義務。
- 分階段推出,並有明確的停止和回滾標準。
資料來源與延伸閱讀
不斷探索
常見問題
Does a strong discovery benchmark prove clinical credibility?
No. Evidence requirements depend on the intended use, data, endpoint, and risk of the decision.